{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:19:42Z","timestamp":1787779182195,"version":"build-2784847793"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471438"],"award-info":[{"award-number":["32471438"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173372"],"award-info":[{"award-number":["82173372"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LDQ24B020002"],"award-info":[{"award-number":["LDQ24B020002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004767","name":"University of Science and Technology Liaoning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031930","name":"Zhejiang Cancer Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.biomaterials.2026.124476","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:05:57Z","timestamp":1784588757000},"page":"124476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rethinking the PSMA-mediated tumor targeting of nanocarrier and potentiating co-delivery of PARP\/EZH2 inhibitors for robust prostate cancer treatment"],"prefix":"10.1016","volume":"336","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2025-6503","authenticated-orcid":false,"given":"Qiang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2849-1015","authenticated-orcid":false,"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-2838","authenticated-orcid":false,"given":"Xiangsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2026.124476_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s44178-024-00118-4","article-title":"CACA guidelines for holistic integrative management of prostate cancer","volume":"3","author":"Dai","year":"2024","journal-title":"Holist. Integr. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41467-024-45307-x","article-title":"Causes of death among people living with metastatic cancer","volume":"15","author":"Mani","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124476_bib3","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biomaterials.2026.124476_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41585-021-00470-4","article-title":"Treatment and trials in non-metastatic castration-resistant prostate cancer","volume":"18","author":"Lokeshwar","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib5","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic Castration-Resistant Prostate Cancer: ASCO Guideline update","volume":"43","author":"Garje","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2967\/jnumed.117.195172","article-title":"Immunohistochemical validation of PSMA expression measured by68 Ga-PSMA PET\/CT in primary prostate cancer","volume":"59","author":"Woythal","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biomaterials.2026.124476_bib7","doi-asserted-by":"crossref","first-page":"16674","DOI":"10.1021\/acsnano.4c01640","article-title":"Enhanced prostate-specific membrane antigen targeting by precision control of DNA scaffolded nanoparticle ligand presentation","volume":"18","author":"Jana","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2026.124476_bib8","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(25)00189-5","article-title":"Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial","volume":"26","author":"Fizazi","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib9","article-title":"Genetically engineered membrane\u2010coated nanoparticles for enhanced prostate\u2010specific membrane antigen targeting and ferroptosis treatment of castration\u2010resistant prostate cancer","volume":"11","author":"Li","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biomaterials.2026.124476_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114614","article-title":"The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2026.124476_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202415322","article-title":"PSMA-targeted nanoparticles with PI3K\/mTOR dual inhibitor downregulate P-glycoprotein and inactivate myeloid-derived suppressor cells for enhanced chemotherapy and immunotherapy in prostate cancer","volume":"37","author":"Yin","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2026.124476_bib12","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1172\/JCI92284","article-title":"Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer","volume":"127","author":"Liu","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biomaterials.2026.124476_bib13","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1038\/s41467-025-61434-5","article-title":"Unlocking tumor barrier: Annexin A2-mediated transcytosis boosts drug delivery in pancreatic and breast tumors","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124476_bib14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.biomaterials.2026.124476_bib15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41565-025-01877-5","article-title":"The pathways for nanoparticle transport across tumour endothelium","volume":"20","author":"Wu","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib16","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1021\/acsnano.1c11578","article-title":"Macrophages actively transport nanoparticles in tumors after extravasation","volume":"16","author":"Lin","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2026.124476_bib17","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1021\/acs.molpharmaceut.4c01252","article-title":"E-Urea-K-Based PSMA imaging served as an alternative in assessing tumor neovascularization via targeting CD31","volume":"22","author":"Wang","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biomaterials.2026.124476_bib19","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1158\/0008-5472.CAN-24-3687","article-title":"Divergent clonal evolution and early dissemination promote genetic heterogeneity of metastases in castration-resistant prostate cancer","volume":"85","author":"Hosseini","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124476_bib20","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.3390\/ijms25094624","article-title":"Homologous recombination repair deficiency in metastatic prostate cancer: new therapeutic opportunities","volume":"25","author":"Piombino","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124476_bib21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome PARP inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124476_bib22","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/onc.2017.311","article-title":"EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer","volume":"37","author":"Yamaguchi","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.biomaterials.2026.124476_bib24","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.2025028560","article-title":"Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer","volume":"146","author":"Zeisig","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2026.124476_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124476_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccell.2019.12.015","article-title":"EZH2 inhibition sensitizes CARM1-High, homologous recombination proficient ovarian cancers to PARP inhibition","volume":"37","author":"Karakashev","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biomaterials.2026.124476_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181062","article-title":"BRCAness, DNA gaps, and gain and loss of PARP inhibitor\u2013induced synthetic lethality","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biomaterials.2026.124476_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl2804","article-title":"EZH2 directly methylates PARP1 and regulates its activity in cancer","volume":"10","author":"Meng","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biomaterials.2026.124476_bib29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biomaterials.2026.124476_bib30","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.7150\/ijbs.109638","article-title":"The mechanism of histone modifications in regulating enzalutamide sensitivity in advanced prostate cancer","volume":"21","author":"Zhao","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124476_bib31","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1021\/acsnano.5b07781","article-title":"Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer","volume":"10","author":"Liu","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2026.124476_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1021\/acsnano.8b06164","article-title":"Improved efficacy and reduced toxicity using a custom-designed irinotecan-delivering silicasome for orthotopic Colon cancer","volume":"13","author":"Liu","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2026.124476_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66061-8","article-title":"Transcytotic transportation of size-controlled nanocarriers into dystrophic skeletal muscle leads to therapeutic outcome in mice","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124476_bib34","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1021\/acsnano.2c02084","article-title":"Quantification of available ligand density on the surface of targeted liposomal nanomedicines at the single-particle level","volume":"16","author":"Chen","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2026.124476_bib35","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.3390\/cancers15225415","article-title":"A comparative analysis of orthotopic and subcutaneous pancreatic tumour models: tumour microenvironment and drug delivery","volume":"15","author":"Fernandez","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2026.124476_bib36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/1078-0432.CCR-18-1382","article-title":"Near-Infrared dye-labeled anti-prostate stem cell antigen minibody enables real-time fluorescence imaging and targeted surgery in translational mouse models","volume":"25","author":"Zhang","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124476_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202101703","article-title":"Multifunctional nanosystems with enhanced cellular uptake for tumor therapy","volume":"11","author":"Ma","year":"2022","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.biomaterials.2026.124476_bib38","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/pros.24237","article-title":"PSMA\u2010positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state","volume":"81","author":"Watanabe","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.biomaterials.2026.124476_bib39","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s11307-024-01920-2","article-title":"Prostate specific membrane antigen expression in a Syngeneic breast Cancer Mouse model","volume":"26","author":"Shirke","year":"2024","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib40","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jconrel.2023.10.038","article-title":"Membrane-derived particles shed by PSMA-positive cells function as pro-angiogenic stimuli in tumors","volume":"364","author":"Machado","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2026.124476_bib41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2406331121","article-title":"3D electron microscopy for analyzing nanoparticles in the tumor endothelium","volume":"121","author":"Mladjenovic","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biomaterials.2026.124476_bib42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41388-024-03232-9","article-title":"EZH2 inhibition sensitizes MYC-high medulloblastoma cancers to PARP inhibition by regulating NUPR1-mediated DNA repair","volume":"44","author":"Yu","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.biomaterials.2026.124476_bib43","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1038\/s41388-025-03466-1","article-title":"LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer","volume":"44","author":"Song","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.biomaterials.2026.124476_bib44","doi-asserted-by":"crossref","first-page":"10585","DOI":"10.18632\/oncotarget.24291","article-title":"Poly(ADP-ribose) polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage","volume":"9","author":"Caruso","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.biomaterials.2026.124476_bib45","article-title":"Combined inhibition of PARP and EZH2 for cancer treatment: current status, opportunities, and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib46","doi-asserted-by":"crossref","first-page":"8733","DOI":"10.1038\/s41467-025-64445-4","article-title":"The interplay of DNA damage, epigenetics and tumour heterogeneity in driving cancer cell fitness","volume":"16","author":"Rouault","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124476_bib47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ejh.13705","article-title":"T cell\u2013mediated autoimmunity in immune thrombocytopenia","volume":"108","author":"Vrbensky","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202403225","article-title":"Reversing EZH2\u2010Mediated epigenetic silence with photodynamic polymeric nanoparticles for synergistically enhanced Antitumor immunotherapy","volume":"34","author":"Cao","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.biomaterials.2026.124476_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2024.107426","article-title":"Bothrops atrox snake venom decreased MHC-II and CD86 expression in bone marrow-derived dendritic cells","volume":"260","author":"Da Silva","year":"2024","journal-title":"Acta Trop."},{"key":"10.1016\/j.biomaterials.2026.124476_bib50","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1021\/acs.chemrestox.6b00357","article-title":"How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction","volume":"30","author":"Cho","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib51","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2009.27.6360","article-title":"Tumor Antigen\u2013targeted, monoclonal antibody\u2013based immunotherapy: clinical response, cellular immunity, and immunoescape","volume":"28","author":"Ferris","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib52","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1038\/s41467-020-17996-7","article-title":"Use of ratiometrically designed nanocarrier targeting CDK4\/6 and autophagy pathways for effective pancreatic cancer treatment","volume":"11","author":"Ji","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124476_bib53","article-title":"Combination chemo\u2010immunotherapy for pancreatic cancer using the immunogenic effects of an Irinotecan silicasome nanocarrier plus Anti\u2010PD\u20101","volume":"8","author":"Liu","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biomaterials.2026.124476_bib54","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124476_bib55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12885-022-09266-0","article-title":"Establishment of an orthotopic prostate cancer xenograft mouse model using microscope-guided orthotopic injection of LNCaP cells into the dorsal lobe of the mouse prostate","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biomaterials.2026.124476_bib56","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1038\/s41388-018-0286-0","article-title":"Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1","volume":"37","author":"Ahmat Amin","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.biomaterials.2026.124476_bib57","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3390\/cancers13051145","article-title":"Novel combinatorial approaches to tackle the immunosuppressive microenvironment of prostate cancer","volume":"13","author":"Shackleton","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2026.124476_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.142912","article-title":"MicroRNAs as the critical regulators of bone metastasis during prostate tumor progression","volume":"309","author":"Moghbeli","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib59","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.eururo.2016.07.033","article-title":"Subgroups of castration-resistant prostate cancer bone metastases defined through an inverse relationship between androgen receptor activity and immune response","volume":"71","author":"Ylitalo","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib60","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/pharmaceutics17050603","article-title":"Nano-drug delivery systems for bone metastases: targeting the tumor\u2013bone microenvironment","volume":"17","author":"Bakir","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biomaterials.2026.124476_bib61","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.actbio.2023.12.040","article-title":"Nano-induced endothelial leakiness-reversing nanoparticles for targeting, penetration and restoration of endothelial cell barrier","volume":"175","author":"Huang","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biomaterials.2026.124476_bib62","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1038\/s41467-025-59381-2","article-title":"Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone niche","volume":"16","author":"Meng","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124476_bib63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrc1528","article-title":"Osteoblasts in prostate cancer metastasis to bone","volume":"5","author":"Logothetis","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124476_bib64","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41585-018-0020-2","article-title":"Translational models of prostate cancer bone metastasis","volume":"15","author":"Berish","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib65","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/cancers12020385","article-title":"Modeling spontaneous bone metastasis formation of solid human tumor xenografts in mice","volume":"12","author":"Labitzky","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2026.124476_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100298","article-title":"Optimization of a syngeneic murine model of bone metastasis","volume":"23","author":"Farhoodi","year":"2020","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.biomaterials.2026.124476_bib67","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1021\/acsabm.5c00403","article-title":"Lipid coating of mesoporous silica nanoparticles leads to efficient antigen delivery to lymph nodes for cancer vaccination","volume":"8","author":"Zhang","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.biomaterials.2026.124476_bib68","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.1021\/acs.jafc.4c12952","article-title":"Influence of modification of cysteine residues in the carbohydrate-binding domain on cellulase activity: achieving enhanced performance and pH-Sensitive recovery","volume":"73","author":"Zhang","year":"2025","journal-title":"J. Agric. Food Chem."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226005004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226005004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:41:17Z","timestamp":1787776877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961226005004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":67,"alternative-id":["S0142961226005004"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124476","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking the PSMA-mediated tumor targeting of nanocarrier and potentiating co-delivery of PARP\/EZH2 inhibitors for robust prostate cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124476"}}